Corpus ID: 40062356

Imaging glioma extent with 131I-TM-601.

@article{Hockaday2005ImagingGE,
  title={Imaging glioma extent with 131I-TM-601.},
  author={David C. Hockaday and Sui Shen and John Fiveash and Andrew Raubitschek and David Colcher and An Liu and Vernon Leon Alvarez and Adam N. Mamelak},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2005},
  volume={46 4},
  pages={
          580-6
        }
}
UNLABELLED TM-601, a 36-amino-acid peptide, selectively binds to glioma cells but not normal brain parenchyma. A phase I/II clinical trial of intracavitary 131I-TM-601 in adult patients with recurrent high-grade glioma was performed to determine the biodistribution and toxicity of this potential therapy. We evaluated imaging and biodistribution data from this trial to assess whether 131I-TM-601 might be useful in determining tumor extent. METHODS Adult patients with recurrent high-grade… Expand

Paper Mentions

Interventional Clinical Trial
The purpose of this study is to evaluate the safety and effectiveness of 131I-TM601 in the treatment of adult patients with progressive or recurrent malignant gliomas.  
ConditionsAstrocytoma, GBM, Glioblastoma Multiforme, (+2 more)
InterventionDrug
Interventional Clinical Trial
The purpose of this study is to evaluate the safety and biologically active dose of TM-601 in adult patients with recurrent malignant glioma.  
ConditionsAstrocytoma, GBM, Glioblastoma Multiforme, (+2 more)
InterventionDrug
Interventional Clinical Trial
This drug is being developed to treat a type of brain cancer, glioma. This study was developed to evaluate the safety, time to disease progression and survival rates after… Expand
ConditionsAnaplastic Astrocytoma, GBM, Glioblastoma Multiforme, (+3 more)
InterventionDrug
Interventional Clinical Trial
This study is designed to evaluate the ability of intravenously (IV)administered 131-I-labeled TM-601 (chlorotoxin) to provide tumor-specific localization(via radiographic… Expand
ConditionsBreast Cancer, Colorectal Cancer, Glioma, (+5 more)
InterventionDrug
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.
  • A. Mamelak, S. Rosenfeld, +13 authors M. Gonda
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
Dosimetry and biodistribution from this first trial suggest that phase II studies of 131I-TM-601 are indicated and may have an antitumoral effect in patients with recurrent glioma. Expand
SPECT imaging and radionuclide therapy of glioma using 131I labeled Buthus martensii Karsch chlorotoxin
TLDR
131I-BmK CT has the potential to be explored as a novel tool for SPECT imaging and radionuclide therapy of glioma and could result in significant tumor inhibition efficacy and prolonging the lifetime of tumor-bearing mice. Expand
Response of Recurrent High-Grade Glioma to Treatment with 90Y-DOTATOC
TLDR
Receptor-mediated radionuclide therapy by locally injected 90Y-DOTATOC is feasible and well tolerated and represents an attractive strategy for the treatment of locally recurring or progressing glioblastoma. Expand
Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601)
TLDR
It is demonstrated that intracavitary dosing of 131I-TM-601 appears safe, minimally toxic, and binds malignant glioma with high affinity and for long durations, and that this peptide represents a potentially important targeting agent for many cancers. Expand
Treatment of high-grade glioma with radiolabeled peptides.
TLDR
This article reviews the literature for PRRT in HGG and describes the peptide receptor radionuclide therapy (PRRT), a new modalities aiming at a tumor-specific treatment sparing normal brain tissue, which is being used in high-grade glioma patients. Expand
Nonclinical Profile of BLZ-100, a Tumor-Targeting Fluorescent Imaging Agent
TLDR
The combined imaging, safety pharmacology, PK, and toxicology studies contributed to an extensive initial nonclinical profile for BLZ-100, supporting first-in-human clinical trials. Expand
Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors.
TLDR
This study provides a preclinical proof of concept for use of this imaging contrast agent BLZ-100 as administered before surgery to dogs with a variety of naturally occurring spontaneous tumors, establishing a foundation that rationalizes clinical studies in humans with soft tissue sarcoma. Expand
Characterization of IRDye 800CW chlorotoxin as a targeting agent for brain tumors.
TLDR
Because increased vascular permeability was observed early in the disease model, larger dye-labeled imaging agents that exceed current BBB size restrictions may warrant renewed consideration as candidates for tumor detection and surgical resection. Expand
Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas.
TLDR
A phase 1 dose-escalation study to characterize the safety, pharmacokinetics, and fluorescence imaging of tozuleristide in adults with suspected glioma suggests that tozulumistide imaging may be useful for FGS of gliomas. Expand
Intracavitary radioimmunotherapy of high-grade gliomas: present status and future developments
TLDR
Intracavitary radioimmunotherapy, in combination with radiotherapy, is discussed in the present review as a therapeutic strategy of high potential and deserves further exploration in future studies by incorporating several innovative modifications. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
  • D. Bigner, M. Brown, +15 authors M. Zalutsky
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
TLDR
The MTD for administration of 131I-labeled 81C6 into the SCRCs of previously irradiated patients with recurrent primary or metastatic brain tumors was 100 mCi and the dose-limiting toxicity was neurologic toxicity. Expand
Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.
TLDR
It was unable to detect a statistically significant difference in sensitivity or specificity between the 201Tl SPECT and FDG PET scans, but this technique should be considered for detection of tumor recurrence with lesions that are demonstrated to be 1.6 cm or larger on CT or MR examinations. Expand
Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial.
TLDR
At 1 year 60% of the patients with astrocytoma with anaplastic foci or glioblastoma multiforme are alive, and the median survival for both groups was 15.6 months. Expand
Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?
TLDR
The data suggest that the ability of FDG PET to differentiate recurrent tumor from radiation necrosis is limited, and both false-positive and false-negative PET scan results contributed to unacceptably low sensitivity and specificity values. Expand
Use of chlorotoxin for targeting of primary brain tumors.
TLDR
In the tumor-bearing severe combined immunodeficient mice, the vast majority of the brain-associated radioactivity was localized within the tumor, suggesting that CTX and CTX-conjugated molecules may serve as glioma-specific markers with diagnostic and therapeutic potential. Expand
Efficacy of Proton Magnetic Resonance Spectroscopy Inclinical Decision Making for Patients with Suspected Malignant Brain Tumors
TLDR
Overall, MRS accurately predicted the pathological nature and clinical outcome of lesions in 15/16 situations, influenced clinical decision making in 12 cases, and altered surgery planning in 7 patients. Expand
Discrimination between neoplastic and nonneoplastic brain lesions by use of proton MR spectroscopy: the limits of accuracy with a logistic regression model.
TLDR
A logistic regression (LR) pattern recognition model was constructed for the discrimination of neoplastic from nonneoplastic brain lesions with MR imaging-guided single-voxel proton MRS data, reflecting high homogeneity among the control spectra. Expand
Focal brain lesions: effect of single-voxel proton MR spectroscopic findings on treatment decisions.
TLDR
MR spectroscopic findings may play a beneficial role in the management of suspected brain tumors and Prospective studies are needed to test the effect of MR spectroscopy on clinical practice and to measure costs and benefits. Expand
Subtraction ictal SPECT co‐registered to MRI improves clinical usefulness of SPECT in localizing the surgical seizure focus
TLDR
It is concluded that SISCOM improves the sensitivity and the specificity of SPECT in localizing the seizure focus for epilepsy surgery and is predictive of postsurgical improvement in seizure outcome. Expand
Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin.
TLDR
The results show that human brain cancers richly express receptors for IL-13, and the interaction detected previously between receptors forIL-13 and IL-4 on solid tumors cell lines is of a qualitatively different character in U-251 MG and U-373 MG glioma cells. Expand
...
1
2
...